Vaxart Secures $25 Million Equity Financing

Vaxart has successfully secured $25 million in equity financing through a deal with Lincoln Park Capital. This significant funding injection is expected to bolster Vaxart's ongoing research and development efforts, particularly in advancing its pipeline of oral vaccines. The capital will likely support clinical trials, manufacturing scale-up, and further corporate initiatives aimed at bringing innovative vaccine solutions to market. This financial milestone underscores investor confidence in Vaxart's technology and its potential to address unmet medical needs in vaccine delivery.